Login to Your Account



Carsgen banks $30M to fund brain, lung, liver cancer phase I trials

By Pearl Liu
Staff Writer

Wednesday, January 27, 2016

HONG KONG – Shanghai-based Carsgen Therapeutics Ltd. closed a $30 million series B financing and now aims to push more of its products to clinical trials at home and abroad. Carsgen plans to complete phase I studies of the two therapeutics, CSG-EGFR and CSG-GPC3 by the end of 2016.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription